Image

Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA

Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA

Recruiting
55-75 years
All
Phase N/A

Powered by AI

Overview

Test of early warning signs and RT-QuIC in patients with idiopathic olfactory dysfunction

Description

Background. The number of persons living with dementia is increasing in Denmark and worldwide because the population is generally growing older. Dementia with Lewy bodies (DLB) is the second most prevalent etiology among the neurodegenerative diseases that give rise to dementia.

DLB is characterized by many prodromal symptoms years before dementia is evident. Currently, little is known about the course of symptoms in the prodromal phase, and furthermore, the diagnosis of DLB can be clinically challenging, especially in the early stages. DLB is like Parkinson's disease (PD), characterized by the accumulation of alpha-synuclein, which misfolds and aggregates within neurons in so-called Lewy Bodies; this assumably drives the neurodegeneration. A novel technique for the measurement of misfolded alpha-synuclein is Real-Time Quaking-Induced Conversion (RT-QuIC), which may be able to support the diagnostic process as well as aid in identifying patients with prodromal DLB. This would enable earlier symptomatic relief and care and potentially promote the search for disease-modifying therapies, which is currently absent.

Objectives. The overarching objective of this project is to identify early clinical warning signs and biomarkers in prodromal DLB.

Method. Study 1: Exploratory cross-sectional case-control study of patients with olfactory dysfunction versus individuals without olfactory dysfunction assessing pathological alpha-synuclein by RT-QuIC and prodromal symptoms of DLB and Parkinson's Disease.

Study 2: Longitudinal follow-up in Danish registries on diagnosing PD and dementia.

Eligibility

Inclusion criteria with patients iOD:

  • Age 55 -75 years of age
  • Slowly progressing and non-fluctuating iOD
  • Able to give informed consent and to cooperate as evaluated by the PI

Exclusion criteria with patients iOD:

  • Diagnosed with a neurodegenerative disease or major neurological/psychiatric condition.
  • Anosmia/hyposmia caused by sino-nasal disease (including chronic rhinitis and allergy), after trauma, infection, congenial, olfactory dysfunction due to surgery, or toxins/drugs affecting the olfactory function.
  • Olfactory dysfunction with response to systemic or local corticosteroids if tried
  • Severe nasal cavity abnormalities or infections.
  • Overt signs of dementia or PD
  • Current alcohol or drug abuse
  • Terminal illness
  • Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.

Inclusion criteria controls:

  • Age 55 -75 years of age
  • Able to give informed consent
  • Able to cooperate as evaluated by the PI

Exclusion criteria controls:

  • Olfactory dysfunction on clinical test
  • Overt signs of dementia or PD
  • Severe nasal cavity abnormalities or infections.
  • Current alcohol or drug abuse
  • Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.

Study details
    Idiopathic Anosmia
    Idiopathic Hyposmia
    Idiopathic Olfactory Dysfunction

NCT05740683

Danish Dementia Research Centre

28 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.